🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

I totally recognize that posting scientific findings to social media is important. But I have been pointed out by our federal representatives that we need to provide a unified voice of concerns about the budget cut for biomedical research. We need to speak up. There are not

☑️#ASCO25 Abstract🆙 ☑️Developmental Tx, Oral 🔥BL-B01D1: EGFR x HER3 bispecific ADC in pts with NSCLC with driver genomic alterations 🎙️ Dr. Yunpeng Yang 🎯ORR: EGFR ex20ins 66.7%, HER2 53.8%, ALK/ROS1/RET 15.8%, KRAS/BRAF/MET 27.3% OncoAlert ASCO meetings.asco.org/2025-asco-annu…

In this #LungCancerConsidered, we discussed in Korean emerging treatments for EGFR+ and HER2+ mutant NSCLC as well as SCLC. Grateful to Dr. So Yeon Kim and Dr. Se-Hoon Lee for sharing their expert insights! Listen here: bit.ly/LCCKor25

In this #LungCancerConsidered, we discussed in Korean emerging treatments for EGFR+ and HER2+ mutant NSCLC as well as SCLC. Grateful to Dr. So Yeon Kim and Dr. Se-Hoon Lee for sharing their expert insights! 많은 청취 부탁드립니다. Listen here: bit.ly/LCCKor25

In this #LungCancerConsidered, we discussed in Korean emerging treatments for EGFR+ and HER2+ mutant NSCLC as well as SCLC. Grateful to Dr. So Yeon Kim and Dr. Se-Hoon Lee for sharing their expert insights! 많은 청취 부탁드립니다. Listen here: bit.ly/LCCKor25

안녕하세요 Don’t miss this IASLC #LungCancerConsidered podcast in Korean🇰🇷 with the awesome Chul Kim discussing EGFR, HER2 targeted therapies #lcsm

#ASCO25 ASCO #NSCLC #LCSM SAVANNAH (Abstract 8513): Phase 2 randomized study of savolitinib + osimertinib vs savolitinib + placebo in EGFRm advanced NSCLC with MET overexpression/amplification post 1L osimertinib: • 🎯 ORR, DoR, and PFS numerically higher with combo • 🧠

I won't be at #ASCO25 red carpet this year, but I'm really exciting for upcoming data in #lungcancer. This is my personal curated list of SOME of the most provocative, impactful, controversial, & intriguing abstracts this year! 🧵

Heading to Chicago! Looking forward to reconnecting with colleagues and friends, and to four days of engagement and learning. #ASCO25

DB-1310, HER3 ADC. - uORR = 31% in solid tumors - uORR = 44% in EGFR-mutant NSCLC - Unadjudicated ILD/pneumonitis = 5.2% (mostly grade 1, 2). Encouraging activity especially in EGFR-mutant NSCLC #ASCO25

BL-B01D1 (iza-bren), EGFRxHER3 ADC in driver mutation positive NSCLC outside of classical EGFR mutant NSCLC ORR in EGFR exon20ins/non classical EGFR NSCLC = 69.2% Activity also noted across other genomic alterations. #ASCO25

Insightful discussion on ADCs by Dr. Siu. Some of the data on HER3-targeted ADCs promising, though further research is needed. Next-gen ADCs should focus on novel target discovery, improved binding, innovative payloads, CNS penetration. The tumor-specific approach was insightful.

Great to see progress in non-classical EGFRm #NSCLC too. More studies are needed. #ASCO25 EGFR Resisters

🆕 #ASCO25 🆙 ☑️Developmental Tx, Oral 🔥MONSTAR-SCREEN-3: Ultra-sensitive pan-cancer #MRD assessment using whole-genome sequencing-based personalized ctDNA panel 🎙️ Dr. Tadayoshi Hashimoto 🎯100% baseline sensitivity (41/41) OncoAlert ASCO LARVOL meetings.asco.org/2025-asco-annu…

TIL therapy is an approved treatment for melanoma (lifileucel; durable response in patients with response) and has shown initial activity in other solid tumors (e.g. lung, GI cancers). An exciting area of investigation that warrants further evaluation. #ASCO2025

What is the potential for CAR T-cell therapy in solid tumors? Early activity has been observed with CAR T cells targeting Claudin-18.2 in gastrointestinal cancers. Careful antigen selection will be critical to ensure safe and effective treatment. #ASCO25

The approval of afamitresgene autoleucel (afami-cel), a TCR therapy for HLA-A*02 and MAGE-A4-expressing synovial sarcoma, highlights the potential for further development of TCR-based therapies in solid tumors. PRAME is another important target for TCR therapy. #ASCO25

Proud of Dr. Tina Roy for presenting her work comparing HIV-pos & HIV-neg NSCLC. Robust lung cancer screening has the potential to improve outcomes (many patients diagnosed at a late stage). Ongoing tumor microenvironment analysis will provide additional insights.

Congratulations to our 🌟 fellow Tina Roy, MD exploring clinical characteristics & treatment outcomes in people living with HIV who develop lung cancer. Georgetown Lombardi. #ASCO25

Blessed to work with dedicated, passionate, and caring fellows everyday! Georgetown Lombardi